{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:01:20Z","timestamp":1793703680137,"version":"4.5.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK113252"],"award-info":[{"award-number":["K23 DK113252"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018578","name":"Clinical and Translational Science Institute, Boston University","doi-asserted-by":"publisher","award":["UL1 TR001430"],"award-info":[{"award-number":["UL1 TR001430"]}],"id":[{"id":"10.13039\/100018578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1053\/j.gastro.2022.06.023","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T22:01:48Z","timestamp":1657749708000},"page":"764-774.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":292,"title":["AGA Clinical Practice Update: Diagnosis and Management of\u00a0Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert\u00a0Review"],"prefix":"10.1053","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-3981","authenticated-orcid":false,"given":"Michelle T.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.06.023_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of\u00a0indications for liver transplant and ethnic and gender\u00a0variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.023_bib4","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2021.07.016","article-title":"Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2022.06.023_bib6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cgh.2020.06.066","article-title":"Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases","volume":"19","author":"Weinberg","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep4.1519","article-title":"Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis","volume":"4","author":"Young","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2022.06.023_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"key":"10.1053\/j.gastro.2022.06.023_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.06.023_bib10","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi","year":"2019","journal-title":"Clin Diabetes"},{"key":"10.1053\/j.gastro.2022.06.023_bib12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib13","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","article-title":"Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral\u00a0obesity","volume":"15","author":"Fracanzani","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib14","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000326","article-title":"Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study","volume":"12","author":"Semmler","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.023_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep4.1124","article-title":"Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study","volume":"2","author":"Hagstr\u00f6m","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2022.06.023_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5009\/gnl210084","article-title":"Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease","volume":"16","author":"Kim","year":"2022","journal-title":"Gut Liver"},{"key":"10.1053\/j.gastro.2022.06.023_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.15403\/jgld-3622","article-title":"Liver-related mortality is increased in lean subjects with non-alcoholic fatty liver disease compared to overweight and obese subjects","volume":"30","author":"Feldman","year":"2021","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1053\/j.gastro.2022.06.023_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/gutjnl-2020-322564","article-title":"Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?","volume":"71","author":"Younes","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.023_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou","year":"2020","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib21","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2022.06.023_bib22","first-page":"S40","article-title":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.06.023_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the\u00a0Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib24","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.06.023_bib25","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.023_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015659","article-title":"Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study","volume":"7","author":"Tanajewski","year":"2017","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2022.06.023_bib27","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2021.04.074","article-title":"Preparing for the NASH epidemic: a call to action","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.023_bib28","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.023_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.023_bib30","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.cgh.2019.11.022","article-title":"Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease","volume":"18","author":"Long","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S2468-1253(17)30052-3","article-title":"Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency","volume":"2","author":"Pericleous","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib32","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jhep.2021.01.045","article-title":"Diagnosis and management of secondary causes of steatohepatitis","volume":"74","author":"Liebe","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib33","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606","volume":"73","author":"Anstee","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrg2322","article-title":"Heritability in the genomics era\u2014concepts and misconceptions","volume":"9","author":"Visscher","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1053\/j.gastro.2022.06.023_bib36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1053\/j.gastro.2022.06.023_bib37","article-title":"Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank","volume":"3","author":"Tavaglione","year":"2021","journal-title":"J\u00a0Hepatol Rep"},{"key":"10.1053\/j.gastro.2022.06.023_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.30799","article-title":"High Risk of fatty liver disease amplifies the alanine transaminase-lowering effect of a HSD17B13 variant","volume":"71","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib40","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1194\/jlr.RA120000907","article-title":"Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity","volume":"61","author":"Ma","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1053\/j.gastro.2022.06.023_bib41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib42","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2022.06.023_bib43","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/hep4.1751","article-title":"Association of genetic risk score with NAFLD in an ethnically diverse cohort","volume":"5","author":"Wang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2022.06.023_bib44","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ajg.2015.235","article-title":"Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy","volume":"110","author":"Wei","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.023_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140427","article-title":"The impact of PNPLA3 rs738409 genetic polymorphism and weight gain >\/=10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals","volume":"10","author":"Nishioji","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2022.06.023_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0022-2275(20)34487-4","article-title":"Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity","volume":"41","author":"Watts","year":"2000","journal-title":"J\u00a0Lipid Res"},{"key":"10.1053\/j.gastro.2022.06.023_bib47","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.29395","article-title":"Interferon lambda 4 rs368234815 TT>deltaG variant is associated with liver damage in patients with nonalcoholic fatty liver disease","volume":"66","author":"Petta","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib48","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.31599","article-title":"NAFLD: reporting histologic findings in clinical practice","volume":"73","author":"Brunt","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib49","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib50","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.023_bib51","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","article-title":"Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations","volume":"116","author":"Younossi","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.023_bib53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2022.06.023_bib54","first-page":"815","article-title":"Derivation and performance of standardized Enhanced Liver Fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis","volume":"3","author":"Day","year":"2019","journal-title":"J\u00a0Appl Lab Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib56","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.023_bib57","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib58","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib59","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.cgh.2019.09.027","article-title":"Performance of simple fibrosis scores in nonobese patients with nonalcoholic fatty liver disease","volume":"18","author":"Fu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib60","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.023_bib61","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour","year":"2021","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1053\/j.gastro.2022.06.023_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.023_bib63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib64","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.023_bib65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib66","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib67","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A\u00a0blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2022.06.023_bib68","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/MEG.0000000000002158","article-title":"Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease","volume":"33","author":"Sinn","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib69","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib70","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib71","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.023_bib72","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/liv.12552","article-title":"Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance","volume":"35","author":"Kwak","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2022.06.023_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046819","article-title":"Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults","volume":"7","author":"Bae","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2022.06.023_bib74","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2009.05.033","article-title":"Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome","volume":"51","author":"Abid","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib75","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib76","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib77","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.06.023_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.105","article-title":"Drug discovery and treatment paradigms in nonalcoholic steatohepatitis","volume":"3","author":"Noureddin","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1053\/j.gastro.2022.06.023_bib79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.06.023_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1053\/j.gastro.2022.06.023_bib81","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.06.023_bib82","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"key":"10.1053\/j.gastro.2022.06.023_bib85","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty\u00a0liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.023_bib86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13104-018-3212-1","article-title":"Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis","volume":"11","author":"Bernhardt","year":"2018","journal-title":"BMC Res Notes"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852200628X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852200628X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:51:44Z","timestamp":1762163504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852200628X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S001650852200628X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.06.023","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Update: Diagnosis and Management of\u00a0Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert\u00a0Review","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}